Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crinetics PharmaceuticalsFRA:6Z4 -1.23%50 Days Payable is 8,030.53 as of Mar. 2026, which is 66% above its 10-year median of 4,827.77. GuruFocus rates FRA:6Z4 with a GF Score™ of 50/100 and a GF Value™ of €626.58 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 702 Biotechnology companies, Crinetics Pharmaceuticals ranks better than 96.72% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Z4 vs CPRX, NAMS, RCUS: Days Payable Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Days Payable falls into.
Crinetics Pharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Crinetics Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (FRA:6Z4) has a Days Payable of 8,030.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Crinetics Pharmaceuticals and its competitors. This is 66% above median its historical median of 4,827.77. Over the past decade, Crinetics Pharmaceuticals' Days Payable has ranged from 4,827.77 to 22,909.59. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #23 out of 702 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Crinetics Pharmaceuticals' Days Payable too high?
Crinetics Pharmaceuticals' current Days Payable of 8,030.53 is 66% above median its 10-year median of 4,827.77. Over the past 10 years, this metric has ranged from a low of 4,827.77 to a high of 22,909.59. The Biotechnology industry median Days Payable is 113.10. Crinetics Pharmaceuticals' value of 8,030.53 is 7000.4% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #23 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Days Payable compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #23 out of 702 companies for Days Payable. This places Crinetics Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Crinetics Pharmaceuticals' value of 8,030.53 is 7000.4% above this benchmark. Historically, Crinetics Pharmaceuticals' own Days Payable has ranged from 4,827.77 to 22,909.59 over the past decade. While the company's 10-year median is 4,827.77 vs. the industry median of 113.10, Crinetics Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Days Payable of 8,030.53 is 7000.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Days Payable is 8,030.53, which is 66% above median its own 10-year median of 4,827.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €626.58, compared to a current price of €70.90 — trading 88.7% below its estimated fair value. The current Days Payable is 8,030.53, which is 66% above median its 10-year median of 4,827.77 and 7000.4% above the Biotechnology industry median of 113.10. Crinetics Pharmaceuticals' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Days Payable is 8,030.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €626.58.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:6Z4:
Days Payable: 8,030.53 (66% above median its 10-year median of 4,827.77)
GF Value™: €626.58 vs. price of €70.90 (88.7% below fair value)
Industry Position: 7000.4% above the Biotechnology median (#23 of 702)
No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score
Get the complete analysis for FRA:6Z4
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Z4 has been successfully added to your 
